DailyIQ
Last updated2 minutes ago

VRTX·Vertex Pharmaceuticals Incorporated

$546.25
-11.71 (-2.10%)
Market Closed (Overnight)$546.12-0.13 (-0.02%)
High
$556.99
Open
$549.50
Market Cap
143.22B
52W High
$560.25
Low
$544.48
P. Close
$546.25
P/E
32.51
52W Low
$374.17
Fwd P/E
25.22
DailyIQ Est.
$597.98
Inst. Ownership
57.6%
Short Interest
1.58%
Days to Cover
3.1
Technical Score (1D)
91
BUY
News Sentiment
53
MIXED
Vortex Energy’s latest announcement—launching a ground‑gravity survey at its 100‑percent owned Robinsons River Salt Project—comes just 15.8 hours after the company’s August technical study. The new survey is intended to fill gaps in the subsurface model, refine reservoir targets, and accelerate the decision‑making process for future drilling. By tightening the data set, VRTX hopes to shorten the path from exploration to production, which could reduce development costs and improve the project’s economic profile over the next 10 trading days. The company’s statement notes that the survey is part of a broader geophysical work plan and does not signal an immediate change in cash flow or production outlook. Investors should watch for the release of the gravity survey results, which will likely be published within the next few weeks, to gauge whether the refined model materially shifts drilling priorities. A more precise target list could prompt a shift in capital allocation, potentially affecting the company’s near‑term capital expenditure plans. Additionally, any indication that the survey confirms a larger or more producible reservoir will likely influence short‑term sentiment and trading activity. Finally, keep an eye on subsequent drilling reports, as the company’s next drilling decision will be the first real test of the survey’s value.
Earnings Summary
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative cystic fibrosis therapies, with a portfolio that includes TRIKAFTA/KAFTRIO and other CF drugs, while expanding into other therapeutic areas such as sickle cell disease and autoimmune disorders. The company operates within the healthcare biotechnology sector, generating significant cash flow from its CF product sales. In Q4 2025, Vertex reported EPS of $5.03 versus an estimate of $5.17, and revenue of $3.19 billion against a $3.24 billion forecast, reflecting a slight EPS miss but a modest revenue beat; this follows Q3 2025 where EPS of $4.80 beat the $4.58 estimate and revenue of $3.077 billion surpassed the $3.07 billion estimate, indicating a consistent earnings beat trend with revenue growth hovering around 3–4% YoY. Across the last eight quarters, Vertex has shown a steady YoY revenue growth trajectory, with EPS generally beating estimates, though the most recent quarter saw a small EPS miss, suggesting tightening margins. Historically, the company has maintained a pattern of strong revenue growth driven by its CF portfolio, while EPS has occasionally lagged due to pricing pressures or cost increases. Recent news highlights senior management appearances at major investor conferences, a $1.42 billion share‑repurchase program, and a strategic collaboration with AbCellera for multispecific T‑cell engagers, all of which reinforce confidence in the company’s cash generation and pipeline diversification. Investors should watch for the next earnings guidance for any revisions, monitor progress on the T‑cell engager program and FDA decisions that could impact valuation, and pay attention to any updates on cost management or pricing power that may influence EPS performance in the coming quarter.

EPS

EstBeatMiss
$1.83$2.78$3.72$4.66$5.60Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.27 - -
Q2'26$4.82$4.73-2.0%
Q1'26$4.39$4.47+1.7%
Q4'25$5.17$5.03-2.7%
Q3'25$4.58$4.80+4.9%
Q2'25$4.25$4.52+6.3%

Revenue

EstBeatMiss
$2.9B$3.1B$3.2B$3.4B$3.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.5B - -
Q2'26$3.3B$3.3B+1.1%
Q1'26$3.1B$3.0B-3.4%
Q4'25$3.2B$3.2B-1.5%
Q3'25 - $3.1B -
Q2'25 - $3.0B -

Market Data

VRTX Stock Snapshot

BUY91/100
$546.12$0.13 (0.0%)
Market cap
143.22B
P/E ratio
32.5
Day range
$544.48 – $556.99
News sentiment
53/100 · Neutral
Analyst target
$569.54 (+4.3%)
Consensus
Buy · 37 analysts
52-week range+46.0% off low · -2.5% from high
$374.17$560.25
Price $546.12 DailyIQ Est. $597.98

Vertex Pharmaceuticals Incorporated screens well technically, with price sitting near its 52-week high. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What VRTX's own history says about today's numbers

Realized volatility (21d)
34.3% 65th pct
Below its peak
0.0%
vs 200-day average
+20.0%
Up days (1y)
48%

Vertex Pharmaceuticals Incorporated is currently running 34.3% annualised volatility over the last 21 sessions. Measured against VRTX's own 13 years of daily returns rather than a market-wide average, that is the 65th percentile a little above its own norm, against a typical reading of 29.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

VRTX is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -25.1%, with the deepest at -41.7% in 2016 — so highs have historically been given back before they were extended.

Price sits +20.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 83rd percentile a wider gap than this stock usually carries. Over the past year VRTX closed higher on 48% of sessions, and it is currently 4 sessions into a rising streak.

On September specifically: over 13 years of records, VRTX finished the month higher 2 of 13 times, with a median return of -3.0% and an average of -2.2%. Its strongest month historically has been June at +5.2% on average, its weakest September at -2.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: VRTX has opened more than 2% away from the prior close in 118 of 3,268 sessions (3.6% of the time), with the largest gaps running +48.0% and -7.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, VRTX moved an average of 3.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +2.6% and a largest of +7.7%.

All figures computed from 3,269 daily closes between 2013-09-05 and 2026-09-03, split-adjusted, recomputed daily. Percentiles are against VRTX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of VRTX's sector?

Vertex Pharmaceuticals Incorporated sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, VRTX ranks 4th of 15 tracked industries, weakening.

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90
Industry rank
#4 of 15

Options Market

What is the options market pricing for VRTX?

CallsPuts

For Vertex Pharmaceuticals Incorporated's nearest expiry (2026-09-04, 0 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.00), with at-the-money implied volatility around 46.5%.

Put/call ratio (2026-09-04)
1.00
ATM implied volatility
46.5%
Total open interest
914

VRTX Competitive Positioning

Vertex Pharmaceuticals Incorporated (VRTX) is tracked alongside these names in Biotechnology on DailyIQ — ranked by market cap, with today's move alongside.